# 2020 QCDR Measure Specifications

# ACR14: Gout: Serum Urate Target

- **QCDR Measure ID:** ACR14
- **National Quality Strategy (NQS) domain:** Effective Clinical Care
- **Measure type:** Intermediate Outcome
- **High Priority:** Yes
- **Meaningful Measure Area:** Management of Chronic Conditions
- **National Quality Forum (NQF) ID:** 2549e
- **Denominator:** Adult patients aged 18 and older with a diagnosis of gout treated with urate lowering therapy (ULT) for at least 12 months.
- **Numerator:** Patients whose most recent serum urate level is less than 6.0 mg/dL
- **Denominator exceptions:** Documentation of medical reason(s) for not expecting a serum urate target level of < 6.0 mg/dL (i.e., any eGFR level < 30 mL/min or Stage 3 or greater chronic kidney disease in the measurement year or year prior)
- **Denominator exclusions:** Patients with a history of solid organ transplant.
- **Numerator Exclusions:** None
- **Risk-adjusted:** No
- **Number of performance rates required for measures:** 1
- **Traditional vs. inverse measure:** Traditional
- **Measure Scoring:** Proportional

# 2020 QCDR Measure Specifications

## ACR12: Disease Activity Measurement for Patients with Psoriatic Arthritis

- **QCDR Measure ID:** ACR12
- **National Quality Strategy (NQS) domain:** Effective Clinical Care
- **Measure type:** Process
- **High Priority:** No
- **Meaningful Measure Area:** Management of Chronic Conditions
- **National Quality Forum (NQF) ID:** n/a
- **Denominator:** Patients 18 years and older with a diagnosis of psoriatic arthritis seen for one or more face-to-face encounters for PsA with the same clinician during the measurement period
- **Numerator:** Number of patients with ≥50% of total number of outpatient PsA encounters in the measurement year with assessment of disease activity using a standardized measure. Acceptable PsA disease activity measurement tools may include, but are not limited to, the following instruments:
    - Physician Global Assessment
    - Patient Global Assessment
    - Patient Pain Visual Analogue Score (VAS)
    - Routine Assessment of Patient Index Data with 3 Measures (RAPID 3)

  A results of any kind qualifies for meeting numerator performance.
- **Denominator exceptions:** None
- **Denominator exclusions:** None
- **Numerator exclusions:** None
- **Risk-adjusted:** No
- **Number of performance rates required for measures:** 1
- **Traditional vs. inverse measure:** Traditional
- **Measure Scoring:** Proportional

# 2020 QCDR Measure Specifications

# ACR11: Hydroxychloroquine Dosing

- **QCDR Measure ID:** ACR11
- **National Quality Strategy (NQS) domain:** Patient Safety
- **Measure type:** Process
- **High Priority:** Yes
- **Meaningful Measure Area:** Preventable Healthcare Harm
- **National Quality Forum (NQF) ID:** n/a
- **Denominator:** Patients 18 years and older seen for a face-to-face encounter who are taking hydroxychloroquine at the most recent encounter during the measurement period.
- **Numerator:** Number of patients whose dose of hydroxychloroquine is ≤6.5 mg/kg
- **Denominator exceptions:** None
- **Denominator exclusions:** None
- **Numerator exclusions:** None
- **Risk-adjusted:** No
- **Number of performance rates required for measures:** 1
- **Traditional vs. inverse measure:** Traditional
- **Measure Scoring:** Proportional

# 2020 QCDR Measure Specifications

## ACR9: Rheumatoid Arthritis Patients with Low Disease Activity or Remission

- **QCDR Measure ID:** ACR9
- **National Quality Strategy (NQS) domain:** Effective Clinical Care
- **Measure type:** Intermediate Outcome
- **High Priority:** Yes
- **Meaningful Measure Area:** Management of Chronic Conditions
- **National Quality Forum (NQF) ID:** n/a
- **Denominator:** Adult patients aged 18 and older with a diagnosis of RA at 2 or more visits 90 days apart
- **Numerator:** At least one disease activity score recorded within the measurement year AND a low disease activity or remission score at the most recent encounter (in the measurement year) where the disease activity was measured. Disease activity must be assessed using one of the following ACR-preferred tools:
    - Clinical Disease Activity Index (CDAI)
    - Disease Activity Score with 28-joint counts (erythrocyte sedimentation rate or C-reactive protein) (DAS-28)
    - Patient Activity Score-II (PAS-II)
    - Routine Assessment of Patient Index Data with 3 Measures (RAPID 3)
    - Simplified Disease Activity Index (SDAI)

  If the patient has more than one measure, the following hierarchy DAS>SDAI>CDAI>RAPID3>PAS-II should be used. In other words, we use the first measures in the hierarchy on a given day and disregard the others.
- **Denominator exceptions:** None
- **Denominator exclusions:** None
- **Numerator exclusions:** None
- **Risk-adjusted:** No
- **Number of performance rates required for measures:** 1
- **Traditional vs. inverse measure:** Traditional
- **Measure Scoring:** Proportional

# 2020 QCDR Measure Specifications

# ACR10: Hepatitis B Safety Screening

- **QCDR Measure ID:** ACR10
- **National Quality Strategy (NQS) domain:** Patient Safety
- **Measure type:** Process
- **High Priority:** Yes
- **Meaningful Measure Area:** Preventable Healthcare Harm
- **National Quality Forum (NQF) ID:** n/a
- **Denominator:** Patients 18 years and older seen for a face-to-face encounter in which a biologic drug or new synthetic immunosuppressive drug is initiated during the measurement period. Drugs include:

  **Biologics:**

  - Abatacept (Orencia)
  - Adalimumab (HUMIRA)
  - Anakinra (Kineret)
  - Belimumab (Benlysta)
  - Canakinumab (ILARIS)
  - Certolizumab (CIMZIA)
  - Etanercept (Enbrel)
  - Golimumab (Simponi)
  - Infliximab (REMICADE)
  - Infliximab-dyyb (Inflectra)
  - Infliximab-abda (Renflexis)
  - Rituximab (Rituxan)
  - Sarilumab (KEVZARA)
  - Secukinumab (Cosentyx)
  - Tocilizumab (ACTEMRA)
  - Ustekinumab (STELARA)

  **Synthetic DMARDs:**

  - Azathioprine
  - Baricitinib (Olumiant)
  - Leflunomide

    - Methotrexate
    - Tofacitinib (XELJANZ)
- **Numerator:** Record of hepatitis B screening documented (hepatitis B surface antigen or hepatitis B viral DNA) anytime in the year prior to drug initiation OR record of hepatitis B treatment 90 days or fewer after drug initiation. Drugs approved for Hepatitis B in the United States include: tenofovir disoproxil, tenofovir alafenamide, entecavir, telbivudine, adefovir dipivoxil, lamivudine.
- **Denominator exceptions:** None
- **Denominator exclusions:** None
- **Numerator exclusions:** None
- **Risk-adjusted:** No
- **Number of performance rates required for measures:** 1
- **Traditional vs. inverse measure:** Traditional
- **Measure Scoring:** Proportional

# 2020 QCDR Measure Specifications

# ACR13: Tuberculosis Test Prior to First Course Biologic Therapy

- **QCDR Measure ID:** ACR13
- **National Quality Strategy (NQS) domain:** Patient Safety
- **Measure type:** Process
- **High Priority:** Yes
- **Meaningful Measure Area:** Preventable Healthcare Harm
- **National Quality Forum (NQF) ID:** n/a
- **Denominator:** Adult patients aged 18 and older who are newly started on biologic therapy during the measurement period
- **Numerator:** Any record of TB testing documented or performed (PPD, IFN-gamma release assays, or other appropriate method) in the medical record in the 12 months preceding the biologic prescription.
- **Denominator exceptions:** None
- **Denominator exclusions:** None
- **Numerator exclusions:** None
- **Risk-adjusted:** No
- **Number of performance rates required for measures:** 1
- **Traditional vs. inverse measure:** Traditional
- **Measure Scoring:** Proportional